{"id":"NCT00091169","sponsor":"ECOG-ACRIN Cancer Research Group","briefTitle":"Levocarnitine in Treating Fatigue in Cancer Patients","officialTitle":"Phase III Randomized Placebo-Controlled Trial to Determine Efficacy of Levocarnitine for Fatigue in Patients With Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12-16","primaryCompletion":"2008-03","completion":"2011-05","firstPosted":"2004-09-08","resultsPosted":"2016-05-30","lastUpdate":"2023-07-05"},"enrollment":376,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Fatigue","Unspecified Adult Solid Tumor, Protocol Specific"],"interventions":[{"type":"DIETARY_SUPPLEMENT","name":"levocarnitine","otherNames":[]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"Arm I","type":"EXPERIMENTAL"},{"label":"Arm II","type":"PLACEBO_COMPARATOR"}],"summary":"RATIONALE: Levocarnitine may help improve energy levels in cancer patients.\n\nPURPOSE: This randomized phase III trial is studying how well levocarnitine works compared to a placebo in treating fatigue in cancer patients.","primaryOutcome":{"measure":"Mean Score Change in Fatigue Measured With Brief Fatigue Inventory From Baseline to 4 Weeks","timeFrame":"assessed at baseline and 4 weeks after randomization","effectByArm":[{"arm":"Levocarnitine","deltaMin":-0.96,"sd":null},{"arm":"Placebo","deltaMin":-1.11,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.57"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":116,"countries":["United States"]},"refs":{"pmids":["22987089"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":166},"commonTop":["Anemia"]}}